Skip to main content
Fred Grossman, DO, Psychiatry, New Hope, PA

FredGrossmanDO

Psychiatry New Hope, PA

Geriatric Psychiatry, Pain Medicine

Physician

Are you Dr. Grossman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 32 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    64 N Main St
    New Hope, PA 18938
    Phone+1 215-862-3321

Summary

  • Dr. Fred Grossman, DO is a board certified psychiatrist in New Hope, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New York, and Maryland.

Education & Training

  • Drexel University College of Medicine/Hahnemann University Hospital
    Drexel University College of Medicine/Hahnemann University HospitalResidency, Psychiatry, 1986 - 1989
  • Nova Southeastern University College of Osteopathic Medicine
    Nova Southeastern University College of Osteopathic MedicineClass of 1986

Certifications & Licensure

  • PA State Medical License
    PA State License 1987 - 2026
  • NY State Medical License
    NY State License 1989 - 2025
  • FL State Medical License
    FL State License 1987 - 2000
  • MD State Medical License
    MD State License 1988 - 1992
  • American Board of Psychiatry and Neurology Psychiatry

Press Mentions

  • Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
    Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceFebruary 23rd, 2024
  • Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
    Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceMarch 1st, 2024
  • Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
    Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s DiseaseMay 23rd, 2024